Koordinierungszentrum für Klinische Studien der Philipps-Universität Marburg

Publikationen 2018

M Friedlander J Rau C K Lee W Meier A Lesoin J-W Kim A Poveda M Buck G Scambia M Shimada  F Hilpert M T King P Debruyne A Bolog S Malander B J Monk E Petru P Calvert T J Herzog C Barrett A du Bois, Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenance therapy, Annals of Oncology, mdx796, https://doi.org/10.1093/annonc/mdx796 Published: 18 December 2017

Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M., Use of antidementia drugs in German patients with Alzheimer’s disease, Int Clin Psychopharmacol. 2017 Nov 6 epub ahead of print

Eugénie Lhommée, Lars Wojtecki, Virginie Czernecki, Karsten Witt, Franziska Maier, Lisa Tonder, Lars Timmermann, Thomas D Hälbig , Fanny Pineau, Franck Durif, Tatiana Witjas, Marcus Pinsker, Maximilian Mehdorn, Friederike Sixel-Döring, Andreas Kupsch, Rejko Krüger, Saskia Elben, Stephan Chabardès, Stéphane Thobois, Christine Brefel-Courbon, Fabienne Ory-Magne, Jean-Marie Regis, David Maltête,Anne Sauvaget, Jörn Rau, Alfons Schnitzler, Michael Schüpbach, Carmen Schade-Brittinger, Gunther Deuschl, Jean-Luc Houeto, Paul Krack, in collaboration with the EARLYSTIM study group, Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial):secondary analysis of an open-label randomised trial, Lancet Neurol 2018; 17: 223–31

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.
A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial. Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.